TY - JOUR
T1 - MAHOGANY
T2 - Margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
AU - Catenacci, Daniel V.T.
AU - Rosales, Minori
AU - Chung, Hyun Cheol
AU - Yoon, Harry H.
AU - Shen, Lin
AU - Moehler, Markus
AU - Kang, Yoon Koo
N1 - Publisher Copyright:
© 2021 Catenacci D et al.
PY - 2021/4
Y1 - 2021/4
N2 - Standard-of-care, first-line therapy for patients with advanced HER2+ gastric/gastroesophageal junction adenocarcinoma is chemotherapy plus trastuzumab, a monoclonal antibody (mAb) targeting HER2. Margetuximab is an Fc-optimized mAb that binds HER2. Retifanlimab, a humanized IgG4 mAb, binds to PD-1 and blocks its interaction with PD-L1/2. Tebotelimab, an IgG4κ bispecific DART® molecule, binds PD-1 and lymphocyte activation gene 3 concomitantly, disrupting these nonredundant inhibitory pathways to further restore exhausted T-cell function. Here, we describe the design and rationale of the randomized, open-label, Phase II/III MAHOGANY trial evaluating margetuximab plus retifanlimab with/without chemotherapy and margetuximab plus tebotelimab with chemotherapy in first-line unresectable metastatic/locally advanced gastroesophageal junction adenocarcinoma. Primary end points include objective response rate, overall survival and safety/tolerability.
AB - Standard-of-care, first-line therapy for patients with advanced HER2+ gastric/gastroesophageal junction adenocarcinoma is chemotherapy plus trastuzumab, a monoclonal antibody (mAb) targeting HER2. Margetuximab is an Fc-optimized mAb that binds HER2. Retifanlimab, a humanized IgG4 mAb, binds to PD-1 and blocks its interaction with PD-L1/2. Tebotelimab, an IgG4κ bispecific DART® molecule, binds PD-1 and lymphocyte activation gene 3 concomitantly, disrupting these nonredundant inhibitory pathways to further restore exhausted T-cell function. Here, we describe the design and rationale of the randomized, open-label, Phase II/III MAHOGANY trial evaluating margetuximab plus retifanlimab with/without chemotherapy and margetuximab plus tebotelimab with chemotherapy in first-line unresectable metastatic/locally advanced gastroesophageal junction adenocarcinoma. Primary end points include objective response rate, overall survival and safety/tolerability.
UR - http://www.scopus.com/inward/record.url?scp=85102076739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102076739&partnerID=8YFLogxK
U2 - 10.2217/fon-2020-1007
DO - 10.2217/fon-2020-1007
M3 - Article
C2 - 33263418
AN - SCOPUS:85102076739
SN - 1479-6694
VL - 17
SP - 1155
EP - 1164
JO - Future Oncology
JF - Future Oncology
IS - 10
ER -
